Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer

Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer

Background: The prognostic factors for efficacy of poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer remain unknown. The purpose of this study is to evaluate the efficacy of PARP inhibitors and to explore their prognostic factors in ovarian cancer.Methods: PubMed, Embase, and conferenc...

Full description

Bibliographic Details
Main Authors: Xuan-zhang Huang, Han Jia, Qiong Xiao, Run-zhou Li, Xing-shuang Wang, Hai-yan Yin, Xin Zhou
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-06-01
Series:Frontiers in Oncology
Subjects:
PARP inhibitors
prognostic factor
BRCA mutation
homologous recombination deficiency
ovarian cancer
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.00958/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.00958/full

Similar Items